Crescent Capital/$CCAP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Crescent Capital
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
- Ticker
- $CCAP
- Sector
- Finance
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Los Angeles, United States
- Website
- www.crescentbdc.com
Crescent Capital Metrics
BasicAdvanced
$378M
-
-$0.00
-
$1.58
13.27%
Price and volume
Market cap
$378M
52-week high
$15.18
52-week low
$8.40
Average daily volume
233K
Dividend rate
$1.58
Financial strength
Current ratio
1.16
Quick ratio
0.518
Long term debt to equity
1.393
Total debt to equity
1.402
Interest coverage (TTM)
2.09%
Profitability
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-0.10%
Operating margin (TTM)
77.66%
Effective tax rate (TTM)
109.51%
Management effectiveness
Return on assets (TTM)
4.57%
Return on equity (TTM)
-0.02%
Valuation
Price to revenue (TTM)
2.49
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
11.425
Free cash flow yield (TTM)
8.75%
Free cash flow per share (TTM)
0.897
Dividend yield (TTM)
15.41%
Forward dividend yield
13.27%
Growth
Revenue change (TTM)
-12.12%
Earnings per share change (TTM)
-100.44%
3-year revenue growth (CAGR)
-3.44%
3-year earnings per share growth (CAGR)
-86.22%
3-year dividend per share growth (CAGR)
0.81%
What the Analysts think about Crescent Capital
Analyst ratings (Buy, Hold, Sell) for Crescent Capital stock.
Analyst projections of the future price of Crescent Capital stock.
Bulls say / Bears say
Third-quarter net investment income was $0.37 per share, above the $0.34 regular dividend, so current earnings still cover the base payout, albeit with a limited cushion. (Crescent Capital BDC)
The company authorised up to $50 million of share repurchases, and Sun Life plans to buy up to a further $25 million in the market. If carried out, these purchases could support demand for the shares and signal backing from its parent. (Crescent Capital BDC)
Credit indicators improved in the second quarter: there were no new non-accrual loans, and existing non-accruals fell to 4.8% of debt investments at cost from 5.7% after restructurings. Management also said about 85% of investments were rated as performing in line with or above expectations. (Investing.com)
NAV per share fell to $17.72 in the third quarter from $19.28 a year earlier, extending the decline and pointing to continued erosion in the value of the portfolio. (Crescent Capital BDC)
Net investment income slipped to $0.37 per share from $0.46 a year earlier, while investment income fell to $36.9 million from $41.4 million. That leaves only a small earnings buffer above the $0.34 regular dividend if income weakens further. (Crescent Capital BDC)
Credit risk remains a concern: at the end of the second quarter, non-accruals were still 4.8% of debt investments at cost and the watchlist had grown to 15% of the portfolio. That leaves CCAP exposed to further losses if troubled borrowers fail to recover. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.
Crescent Capital Financial Performance
Revenues and expenses
Crescent Capital Earnings Performance
Company profitability
Upcoming events
Crescent Capital News
AllArticlesVideos
Funds containing Crescent Capital
Fund name | Fund size | $CCAP weighting |
|---|---|---|
iShares Listed Private Equity$IDPE | $843M | 0.12% |
iShares Listed Private Equity£IPRV | $843M | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.